Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice

Novo Nordisk

Status: Completed

Conditions: Haemophilia B With Inhibitors; Haemophilia A With Inhibitors; Congenital Bleeding Disorder

Treatments: Drug: eptacog alfa (activated)

Study type: Observational

Funder types: Industry

Identifiers

NCT01579955

F7-1947

Details and patient eligibility

About

This study is conducted in Japan. The aim of this non-interventional study is to investigate the safety and effectiveness of treatment with eptacog alpha (NovoSeven®) under normal clinical practice conditions.

Enrollment: 321 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with haemophilia A and B with inhibitors who received eptacog alpha (NovoSeven®) as treatment

Exclusion criteria

• Patients who was not deemed to be appropriate to the treatment of eptacog alpha (NovoSeven®)

Trial design

321 participants in 1 patient group

eptacog alpha users

Treatment:

Drug: eptacog alfa (activated)